SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 17, 1998
THE COVALENT GROUP, INC.
------------------------
(Exact name of issuer as specified in charter)
NEVADA 0-21145 23-561668867
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation or file Identification
Organization) number) Number)
ONE GLENHARDIE CORPORATE CENTER
1275 DRUMMERS LANE
SUITE 100
WAYNE, PENNSYLVANIA 19087
(Address of principal executive offices)
(610) 975-9533
(Registrant's telephone number, including area code)
ITEM 5. OTHER EVENTS.
As is more fully described in the attached press releases, the Company has
recently entered into a multi-year contract for clinical development studies
with an aggregate estimated value of approximately $4 million. See the attached
press release for more detailed information.
This report, including the press release attached hereto, contains
statements that are not based on historical fact and are "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. Among other things, they regard the Company's liquidity, financial
condition, operational matters and the potential revenues to be received from
new contracts. Words or phrases denoting the anticipated results of future
events, such as "anticipate," "believe," "estimate," "expects," "may," "will
continue," "project," and similar expressions that denote uncertainty are
intended to identify such forward-looking statements. Additionally, from time
to time, the Company or its representatives have made or may make oral or
written forward-looking statements. Such forward-looking statements may be
included in various filings made by the Company with the Securities and Exchange
Commission, or in other press releases or oral statements made by or with the
approval of an authorized executive officer of the Company. The Company's
actual results, performance or achievements could differ materially from the
results expressed in, or implied by, such forward-looking statements: (1) as a
result of risks and uncertainties identified in the Company's publicly filed
reports and registration statements; (2) as a result of the outcome of the
contract described in the press release attached hereto; (3) as a result of
factors over which the Company has no control, including the strength of
domestic and foreign economies, the overall CRO and pharmaceutical industries,
sales growth, competition and certain cost increases; or (4) if the factors on
which the Company's conclusions are based do not conform to the Company's
expectations.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits
Exhibit No. Description
----------- -----------
99.1 Press release dated December 17, 1998
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned duly authorized.
Date: December 22, 1998 Covalent Group, Inc.
/s/ William K. Robinson
-------------------------
William K. Robinson
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Press release dated December 17, 1998